StudyFinder

Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

Search all categories
589 Study Matches

Smart Connected Water Bottle and Lighting Devices: A Prenatal Pilot Study

We will conduct a pilot study to test feasibility of an innovative light device and blue-light glasses for promoting better sleep and a novel, smart water bottle for proper hydration. We will also examine women’s sleep and hydration behaviors in relation to their perceptions of pain, and obtain feedback from the participants on the overall patient intervention content to reduce prescription opioid use and promote behavioral pain management strategies after delivery.

Currently recruiting pregnant women who are in their 2nd or 3rd trimester. Attend a pre-session (in person OR remote) to explain the use of the water bottle, lighting devices, activity monitors, and weight scale Use the devices for 22 days and complete surveys in your own home Attend a post-session (in person OR remote) to return devices and participate an interview about the last 22 days

$100

Yes
 

Danielle Downs
Abigail Pauley - at amp34@psu.edu
Kinesiology (UNIVERSITY PARK)
 

Female
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00019938
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Pregnant
2nd or 3rd trimester
18-45
Reside around State College, PA

Exclusion Criteria:
Sleep apnea/diagnosed sleep disorders
Diagnosed eating disorders/extreme dietary restrictions
Currently diagnosed with gestational diabetes
Currently diagnosed with pre-eclampsia
Not pregnant
Pregnancy & Infertility, Sleep Management, Women's Health
Survey(s)
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,

The Effects of Aircraft Seat Width on Passenger Comfort

The objective of this research is to determine the relationship between aircraft seat width and passenger comfort. Airlines are reducing the sizes of seats and improving their ability to fly planes at or near capacity. The combined effect is to decrease the quality of the experience of passengers. This work will help us to understand the degree to which comfort has been reduced.

Participants visit once, for about an hour. During that visit we will measure several body dimensions. Then the participant will evaluate a number of seating conditions for comfort and acceptability.

$20

Yes
 

Matthew Parkinson
Ming-Hua Chang - at AirplaneSeating@psu.edu
School of Engineering Design and Innovation (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00012135
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
We are particularly interested in small and large participants.
You must be a healthy adult aged 18 years or older.

Exclusion Criteria:
Individuals under 18 years of age are not eligible.
Education, Muscle & Bone, Mental & Behavioral Health
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,

Bridging the Workforce Gap in the U.S. Semiconductor Industry

Emerging technologies, particularly in the semiconductor industry, are advancing at an extraordinary pace in the United States, creating an urgent demand for a highly skilled workforce. In 1990, the U.S. held 37% of the global semiconductor manufacturing market; today, that share has sharply declined to just 12% (MASH, 2024). Meanwhile, most semiconductor production has moved overseas, with Taiwan alone accounting for nearly 60% of global output. This concentration of manufacturing capacity in East Asia is increasingly concerning, especially given China’s strategic goal to secure Taiwan by 2030. As such, the U.S. semiconductor supply chain has become a critical national security issue, further emphasizing the immediate need to rebuild a robust domestic manufacturing workforce. To reverse this trend, it is estimated that the U.S. will need an additional 230,000 skilled workers to double its semiconductor market share and regain competitiveness on the global stage (Lightcast, 2023). Achieving this goal requires a significant investment in education and training programs. The HI-TECH (High-Impact Technology Experiential Career Hub) program directly addresses this challenge by offering 75 recent graduates from Career and Technical Education (CTE) programs summer internships in the semiconductor industry over the next three years. These internships will provide invaluable hands-on experience, positioning participants for lucrative, high-demand careers in this vital and rapidly expanding sector. Through this initiative, HI-TECH aims to play a key role in strengthening the U.S. workforce, enhancing national security, and securing America’s future competitiveness in the global semiconductor market.

Participants will be asked to complete an online survey (15-20 minutes) about their experiences with CTE programs, employment in the semiconductor industry, and workforce readiness. Some participants may also be invited to participate in a 30-45 minute interview (conducted via Zoom) to provide further insights.

No
 

Mark Threeton
Mark Threeton - at mdt177@psu.edu or 814-863-5361
Learning and Performance Systems (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00026520
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
18 years of age or older
Recent graduate (within the last two years) from a Career and Technical Education (CTE) programs
CTE administrator or educator involved in curriculum design for semiconductor-related fields

Exclusion Criteria:
Individuals under the age of 18
Individuals who did not complete a CTE program related to semiconductor technology
Individuals unwilling to complete an online survey or interview
Individuals who did not complete a CTE program related to semiconductor technology
Education
Survey(s)
I'm interested
Share via email

Feasibility, Safety and Acceptability of a Mobile Health Delivered Exercise Training Program in Patients with Nonalcoholic Steatohepatitis

This study will be a pilot study to evaluate the workability, safety and acceptability of Exercise and Liver FITness (EL-FIT), a mHealth exercise training program previously confirmed in patients with cirrhosis,(1) in patients with Nonalcoholic Steatohepatitis (NASH)

El-Fit NASH (Nonalcoholic Steatohepatitis) is a 9-week intervention trial for patients with NASH. Our goal is to evaluate the workability, safety and acceptability of Exercise and Liver FITness (EL-FIT), a mHealth exercise training program. The El-FIT application allows for participants to access to a library of guided workouts. All patients will be asked to complete a screening visit that includes a physical exam, height, and weight measurements & surveys. Participants will be asked to download the EL-Fit NASH application and use it for 8 weeks. In addition to using the application, participants will be asked to complete 3 check-in phone calls through-out the 8 weeks.

Yes
 

Justin Tondt
Stine Laboratory at StineLaboratory@pennstatehealth.psu.edu or 717-531-0003, ext=320222
Family and Community Medicine (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT06195943
STUDY00022771
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
18 years or older
Evidence of NASH
Posission of a Smart Phone

Exclusion Criteria:
Active cardiac Symptoms
Active or recent participation in exercise training program within the last 90 years
Active or recent weight-loss supplement use within the last 90 days
Active illicit substance use
Cancer that is active
Digestive Systems & Liver Disease, Sports Medicine
Not applicable
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

PSCI 24-077 A Phase 1b/2 Study Assessing the Safety and Efficacy of Evexomostat (SDX-7320) in Combination with a PI3K Pathway Inhibitor plus Fulvestrant in Postmenopausal Women with Advanced Breast Cancer and PI3K Pathway Alterations Who Have Progressed on or Following Endocrine Therapy plus a CDK4/6 Inhibitor

this trial is looking at introducing a medication to control blood sugars elevations caused by CDK inhibitors.

Participants must agree to come to all study visits, report any new medications to the study team, agree to having blood work done at least 8-12 hours after eating something, take study medication as directed.

Yes
 

Monali Vasekar
PSCI-CTO@pennstatehealth.psu.edu 717-531-5471
Medicine: Hematology and Medical Oncology (HERSHEY)
 

Female
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT05570253
STUDY00025502
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Patient is an adult female ≥18 years old at the time of informed consent(s) and has signed informed consent(s) before any trial related activities and according to local guidelines.
Patient with histologically and/or cytologically confirmed diagnosis of HR+, HER2- breast cancer, as determined by the local laboratory.
Patient has identified PI3K pathway
Patient has locally advanced (not amenable to curative therapy or metastatic) breast cancer meeting any of the following categories:
Patient has measurable disease

Exclusion Criteria:
Patient has inflammatory breast cancer at screening.
Patient has known primary brain malignancy,
Patient has a known hypersensitivity to evexomostat, fulvestrant, alpelisib or capivasertib, or to any of their excipients.
Patient has had major surgery within 30 days
Patient has uncontrolled human immunodeficiency virus (HIV) infection.
Cancer
Experimental drug compared to an approved drug
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Effects of fasting on blood protein levels

Up to 50 older adults (age 60+ years) will participate in a two-visit CRC study with blood sampling (40 ml per visit) occurring before and after a breakfast meal. Specifically, there will be four (10 ml) blood draws during each of the visits, with each blood draw timed one hour apart (T1 to T4). The two visits (short- and long-fasting) will be randomly assigned and counterbalanced for the order in which they occur and will occur at least a week apart. During the short-fasting visit, participants will arrive fasting and be given breakfast after the second blood draw (T2). During the long-fasting visit, participants will arrive fasting and be given breakfast after the fourth blood draw (T4). Aside from blood draws, and vitals obtained at the start of each visit, participants will be seated comfortably in a chair in a small room by themselves. They will be checked upon periodically to ensure they are not falling asleep, they are comfortable, etc. They will also be given a small packet of written questionnaires to complete after T1 and after T3 (i.e., after the 1st and 3rd blood draws). Each visit will be between 3.5 and 4 hours.

There will be two in-person visits both will include four blood draws.

$100 total

Yes
 

Christopher Engeland
Abigail Smith - at ajs8854@psu.edu or 814-867-5428
Biobehavioral Health (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00021531
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Men and women between the ages of 60-90
Fluent in English
Vaccinated for COVID-19

Exclusion Criteria:
Non-ambulatory
Having current severe psychiatric symptoms that interfere with testing
Alcohol or substance abuse, chronic medicinal use of opioids, glucocorticoids, anti-inflammatories, or active cancer treatment in the last 12 months
Education
Survey(s)
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,

PSCI 23-012 THE JANUS RECTAL CANCER TRIAL: A RANDOMIZED PHASE II TRIAL TESTING THE EFFICACY OF TRIPLET VERSUS DOUBLET CHEMOTHERAPY TO ACHIEVE CLINICAL COMPLETE RESPONSE IN PATIENTS WITH LOCALLY ADVANCED RECTAL CANCER

This trial is using long course chemoradiation in combination with three different chemotherapy treatments to treat rectal cancer. Once therapy is completed patients will either have surgery or watch and wait. The goal is to see which therapy is better in achieving a complete response, if any.

Patients will be expected to come to the clinic for all radiation treatments and all chemotherapy treatments.

Yes
 

Mitchell Machtay
PSCI-CTO@pennstatehealth.psu.edu
Medicine: Hematology and Medical Oncology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT05610163
SITE00001341
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Clinical stage II or III rectal adenocarcinoma defined as T4N0 or any T with node positive disease (any T, N+); also T3N0 requiring APR or coloanal anastomosis
Tumor Site: Rectum; ≤ 12cm from the anal verge
No prior systemic chemotherapy, targeted therapy, or immunotherapy; or radiation therapy administered as treatment for colorectal cancer within the past 5 years is allowed.
Not pregnant and not nursing,
Age ≥ 18 years

Exclusion Criteria:
No upper rectal tumors (distal margin of tumor >12 cm from the anal verge)
No recurrent rectal cancer; prior transanal excision, prior distal sigmoid cancer with a low anastomosis
No known mismatch repair deficient rectal adenocarcinoma
Cancer
Approved drug(s)
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Phase III Trial of MEDI4736 (durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC (EA5181) (PSCI# 21-041)

The purpose of this study is to compare the usual approach of chemo/radiation followed by one year of MEDI4736 (durvalumab) to chemo/radiation with MEDI4736 (durvalumab) followed by one year of MEDI4736 (durvalumab). The addition of MEDI4736 (durvalumab) during chemo/radiation could prevent your cancer from returning and extend your life. But, it could also cause side effects. This study will help the study doctors find out if this different approach is better, the same, or worse than the usual approach. To decide if it is better, the study doctors will be looking to see if the study drug extends the life of patients and/or prevents the tumor from coming back as compared to the usual approach. This drug, MEDI4736 (durvalumab), is already approved by the FDA for use in other cancers, and for use in your type of cancer after the completion of chemotherapy and radiation. At this time MEDI4736 (durvalumab) is not yet approved (experimental) when given with chemotherapy and radiation. There will be about 660 people taking part in this study.

The purpose of this study is to compare the usual approach of chemo/radiation followed by one year of MEDI4736 (durvalumab) to chemo/radiation with MEDI4736 (durvalumab) followed by one year of MEDI4736 (durvalumab). The addition of MEDI4736 (durvalumab) during chemo/radiation could prevent your cancer from returning and extend your life. But, it could also cause side effects. This study will help the study doctors find out if this different approach is better, the same, or worse than the usual approach. To decide if it is better, the study doctors will be looking to see if the study drug extends the life of patients and/or prevents the tumor from coming back as compared to the usual approach. This drug, MEDI4736 (durvalumab), is already approved by the FDA for use in other cancers, and for use in your type of cancer after the completion of chemotherapy and radiation. At this time MEDI4736 (durvalumab) is not yet approved (experimental) when given with chemotherapy and radiation. There will be about 660 people taking part in this study.

Yes
 

Patrick Ma
PSCI-CTO@pennstatehealth.psu.edu 717-531-5471
Medicine: Hematology and Medical Oncology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT04092283
SITE00000978
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Patient must be = 18 years old.
Patient must have an ECOG Performance Status of 0 or 1.
Body weight > 30 kg of patients.
Patient must not have unintentional weight loss > 10% within 30 days prior to registration.
Patient must have a baseline ECG obtained within 6 weeks of registration.

Exclusion Criteria:
Patient must not have any active, known or suspected autoimmune disease and neuromuscular paraneoplastic syndromes
Patient must not have a history of active hepatitis B (chronic or acute) or hepatitis C infection.
Patient must not have a known active tuberculosis infection.
Patient must not have any severe infections within 4 weeks prior to registration including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia.
Patient must not have signs or symptoms of severe infection (sepsis) within 2 weeks prior registration.
Cancer
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

CAREER: No Time to Explain: Developing Robots that Actively Prevent Overtrust during Emergencies

The overall goal of this proposal is to develop robots that can help people correctly calibrate their trust in the robot. We look at this problem within the context of robot-guided emergency evacuation. We believe that robots stationed inside of buildings can serve as instantaneous first responders helping people safely evacuate during an emergency, thus saving lives. Participants will be asked to interact with an emergency guidance robot and decide whether to follow the robot to an exit.

Yes
 

Alan Wagner
Alan Wagner - at azw78@psu.edu
Aerospace Engineering (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00016965
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Over 18
Reasonable ability to see

Exclusion Criteria:
Under 18
Cannot see or read the consent form
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,

GPRPL Study

The purpose of this study is to find genetic causes of recurrent pregnancy loss (RPL). RPL is defined by two or more miscarriages under 20 weeks gestation and affects approximately 5% of women. The causes of RPL are not well understood. After all the currently recommended testing for RPL has been done, about half of women with RPL will still have no identifiable cause. This lack of knowledge makes it difficult to provide effective medical care for couples with RPL. This study will compare reading about 20000 genes in the entire human genetic library by whole genome sequencing in the miscarriage material and also your and your partner’s DNA from blood samples. The DNA in a person is a combination of the DNA from each of their biological parents. If you have healthy children we may ask your consent for them to give a blood sample for DNA extraction and testing. Similarly, we may ask the same for other family members such as grandparents if necessary. We may also request your permission to use stored DNA or miscarriage material from previous pregnancy loss if available. Testing of family members or previous miscarriage materials may help to understand DNA sequence variants or changes identified in the miscarriage sample.

There will be a one time collection of blood samples.

Yes
 

Sarah Horvath
OBGYNResearch@pennstatehealth.psu.edu
Obstetrics and Gynecology (HERSHEY)
 

Female
18 year(s) or older
This study is also accepting healthy volunteers
SITE00001050
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Women with current pregnancy loss
Two or more prior losses of clinically recognized pregnancies
Prior losses are unexplained

Exclusion Criteria:
Known cause for pregnancy loss and/or prior losses
Pregnancy & Infertility
Prefer not to display
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

ALL ALS-ASSESS

This study will follow symptomatic ALS participants and control participants for 2 years, measuring a wide range of ALS outcome measures and gathering long term survival data.

Study visits will be conducted both in an in-clinic setting (on-site) and remotely (off-site) over the course of 24 months (2 years). The symptomatic ALS cohort participants can either participate in on-site or off-site visits, depending on their location and ease of access to one of the participating sites. During this 2-year period, symptomatic ALS participants will complete a screening visit (2-3 hours to complete), a total of 7 in-person study visits (1-3 hours to complete) and 24 remote self-assessment activities (completed each month, takes 35-45 minutes to complete). Participants and will need access to a personal device (i.e. a computer and/or smartphone or tablet) and an internet connection to participate in this study. All control participants will participate on-site, completing their on-site visits every 12 months. Biospecimens will be collected at regular intervals to support biofluid biomarker analyses. Biospecimens will include plasma, serum, whole blood for generation of induced pluripotent stem cells (iPSCs) and DNA for whole genome sequencing, and cerebrospinal fluid (CSF). For on-site symptomatic ALS and control participants, CSF will be collected through optional Lumbar Puncture (LP) procedure. Only plasma, serum and whole blood will be collected for off-site participants through home phlebotomy collection process.

Up to $350

Yes
 

Zachary Simmons
nervemuscle@pennstatehealth.psu.edu 717-531-8257
Neurology (HERSHEY)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00024206
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Age 18 years or older
Capable of providing informed consent
Willing to follow study procedures
Diagnosis of ALS by a physician
Access to a smartphone, computer or tablet, and internet (need not be in the home – access to a public library or other available computer with internet connection is sufficient)

Exclusion Criteria:
Significant cognitive impairment, clinical dementia, or unstable psychiatric illness, including psychosis, active suicidal ideation, suicide attempt, or untreated major depression that would interfere with the study procedure.
Clinically significant unstable medical condition (other than ALS) that would render the participant unlikely to be able to complete 12 months of follow-up, according to Investigator’s judgment.
Optional Lumbar Puncture - Medically unable to undergo LP; allergy to Lidocaine or other local anesthetic agents; use of anticoagulant medication or antiplatelet medications (aside from aspirin 81mg) that cannot be safely withheld prior to LP.
Neurology
Not applicable
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Endometriosis and microvascular dysfunction

Endometriosis, is a disorder that occurs in women, is when tissue that should be normally found inside the womb is also found in sites outside of the womb. This disorder impairs the function of the endothelium, the cells that line the body’s blood vessels (endothelium). The endothelium helps to control blood flow in healthy vessels. Women with this disorder not only have an increased risk for high blood pressure and high cholesterol, they also have an increased risk for cardiovascular disease. They have a higher risk for cardiovascular disease, too. With this study, we will learn how endometriosis impairs the lining of blood vessels and increases the risk for disease. We will test two different intervention strategies to reduce long-term cardiovascular disease risk in women with endometriosis.

There will be 3 in person visits, blood draws will occur at all visits. On 2 of the visits blood flow experiments will be conducted. Participants will take oral medications.

390

Yes
 

Lacy Alexander
Susan Slimak - at sks31@psu.edu or 814-863-8556
Kinesiology (UNIVERSITY PARK)
 

Female
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT05059626
STUDY00018347
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Women, 18-45 years of age
Endometriosis

Exclusion Criteria:
Tobacco consumption (e.g. smoking)
Pregnant and/or breastfeeding
Taking blood pressure medication
Heart & Vascular, Pregnancy & Infertility, Women's Health
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 5 locations

Study Locations

Hide all locations
Location Contacts
Altoona, PA ,
Harrisburg, PA ,
Hershey, PA ,
State College, PA ,
Williamsport, PA ,

Human-Centric Non-Invasive Physiological Sensing System for Early Detection of Workers’ Heat Stress in the Field

This study will examine different structural designs of stretchable, skin-like sensors on the surface of human skin for workers.

There will be one in person visit; Subjects will first be asked to sit still for 3 minutes and then move their skin by the research team for another 3 minutes.

Yes
 

Huanyu Cheng
Huanyu Cheng - at huc24@psu.edu or 814-863-5945
Engineering Science and Mechanics (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00020880
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
no existing skin conditions or open wounds, or other disorders that make them have altered temperature responses
be over 18 years old
must understand English
resources from Penn State, University Park

Exclusion Criteria:
people with a metal allergy
Men's Health, Women's Health
Prefer not to display
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,

Voice Perception Study

This is a voice perception study that asks participants to listen to voices and rate on various attributes such as attractiveness, social status, health, and others.

No
 

Toe Aung
Toe Aung - at txa96@psu.edu or 775-225-1747
Anthropology (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
STUDY00009763
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Age 18-40
Gender/Sex: Men/Male; Women/Female
Education: PSU students and participants recruited online

Exclusion Criteria:
Uncorrected severe defects of hearing
Participants who already completed the survey
Participants who took the survey on the mobile phone
Men's Health, Women's Health
I'm interested
Share via email

A multicenter safety study of unlicensed, investigational cryopreserved cord blood units (CBUs) manufactured by the National Cord Blood Program (NCBP) and provided for unrelated hematopoietic stem cell transplantation of pediatric and adult patients

Study of the safety of unlicensed cord blood units for stem cell transplant of children and adults.

For the treatment arm of this study you will no receive the total body radiation (TBI) as typically given before transplant. In this study you will have various research procedures such as a Blast sample at the screening part of the study, and MRD testing of your bone marrow and blood at screening and through the course of the study. Participation in the treatment arm (Non-TBI) of the study will last up to 5 years.

Yes
 

Valerie Brown
Suzanne Treadway - at streadway@pennstatehealth.psu.edu or 717-531-3097
Pediatrics: Hematology/Oncology (HERSHEY)
 

All
All
This study is NOT accepting healthy volunteers
NCT01656603
STUDY00015052
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
You have a disorder affecting your hematopoietic system (the organs and tissues that produce your blood) that is inherited, acquired, or from previous chemotherapy

Exclusion Criteria:
You are receiving licensed cord blood products
You are receiving unlicensed CB products from other CB banks
Blood Disorders, Cancer
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Emotion in Motion: Behavior and Mental State Analysis on Human Visual Data

The main purpose of the proposed study is to examine the relationship between emotional body expression and internal emotional and psychophysiological processes among individuals with mental disorders in social interaction situations.

In this study, participants will be asked to answer structured questions. After this, participants will be asked to engage in emotional induction tasks, communicate with another person, and walk. During the interview and experimental procedures, your motion will be video recorded.  

40

Yes
 

James Wang
Adam Calderon - at afc6160@psu.edu or 814-863-0115
Information Sciences and Technology (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00006792
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
You are at least 18 years old
Fluent in English
Able to walk at a leisurely pace on a treadmill without assistance

Exclusion Criteria:
Under 18 years old
Not fluent in English
Unable to walk at a leisurely pace on a treadmill without assistance
Experiencing cognitive impairments
Mental & Behavioral Health
Not applicable
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,

A prospective examination of TAC features as predictors of consequences and alcohol use disorders

The study aims to use a longitudinal design that combines transdermal alcohol concentration (TAC) sensors and ecological momentary assessment (EMA) in a sample of college and non-college young adults to examine the associations between TAC features (such as rise rate and duration), alcohol-related consequences, and alcohol use disorder (AUD), when adjusting for EMA self-reported indicators (such as drink counts, estimated BAC).

If eligible, participants will be invited to be part of a study that will take place over two years. Every 6 months, participants will be asked to wear a small biosensor on their wrist and complete mobile phone surveys for three consecutive weeks. Participants will also be asked to complete a 20-minute survey and a 15-minute interview at baseline, 12-month, and 24-month follow-ups. Participants can earn up to $776 over the course of the two-year period. 

776

Yes
 

Michael Russell
Sarah Ackerman - at psuprohealth@psu.edu
Human Development and Family Studies (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00025265
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Must be aged 19-20 years old
Must have a working iPhone (biosensor app is iOS compatible only)
Must be willing and able (ex. no app store issues such as expired payment method, have space on phone) to download and install two free apps from app store
Must live/work/attend school in the State College, PA area (biosensor pick up on University Park campus)
Must not be participating in another study with mobile phone survey currently or planning to participate in another study with mobile phone survey in next 30 days

Exclusion Criteria:
Not aged 19-20 years
Dot not have a working iPhone
Not able/willing to download and install two free study apps from app store
Do not live, work, or attend school in the State College, PA area
Are participating or plan to participate in the next 30 days in another study with mobile phone surveys
Addiction & Substance Abuse
Not applicable
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,

Phase III Trial of Concurrent Chemoradiotherapy with or without Atezolizumab (PSCI# 19-044)

The purpose of this study is to compare the effects, good and/or bad, of chemotherapy and radiation therapy with or without the use of atezolizumab, which is used to treat bladder cancer. The combination of chemotherapy, radiation therapy and the immunotherapy atezolizumab is considered experimental.

The purpose of this study is to compare the effects, good and/or bad, of chemotherapy and radiation therapy with or without the use of atezolizumab, which is used to treat bladder cancer. The combination of chemotherapy, radiation therapy and the immunotherapy atezolizumab is considered experimental. If you decide to take part in this study, you will receive combined chemotherapy and radiation therapy which is called “chemoradiotherapy” either with or without the study drug. The chemoradiotherapy you will receive is standard of care and what your doctor thinks is best. You will receive chemoradiotherapy for up to 7 weeks. If you are assigned to the group receiving study drug, you will take the drug for up to 6 months in addition the chemoradiotherapy. Your doctor will continue to follow your condition for up to 5 years after you register to the study, even though you have finished treatment in the first year. Your doctor will watch you for side effects and to see how your cancer affects you. You will have clinic visits at 3 months from the time you stop taking treatment for the first two years and then twice a year for the third year and once a year thereafter until 5 years after you register to the study

Yes
 

Monika Joshi
PSCI-CTO@pennstatehealth.psu.edu 717-531-5471
Medicine: Hematology and Medical Oncology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03775265
SITE00000631
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Patients must have histologically proven, T2-T4a N0M0 urothelial carcinoma of the bladder within 70 days prior to randomization.
Patients must undergo radiological staging within 70 days prior to randomization. Imaging of chest, abdomen, and pelvis must be performed using CT or MRI. Patients must not have evidence of T4bN1-3 disease.
Patients with hydronephrosis are eligible if they have unilateral hydronephrosis and kidney function meets criteria specified.
Female patients of childbearing potential must have a serum pregnancy test prior to randomization.
Patients must be ≥ 18 years of age.

Exclusion Criteria:
Patient must not have received any systemic chemotherapy for their bladder cancer.
Patients must not have received prior treatment for muscle invasive bladder cancer including neoadjuvant chemotherapy for the current tumor.
Patients must not have a major surgical procedure within 28 days prior to randomization.
Patients must not have undergone prior allogeneic bone marrow transplantation or prior solid organ transplantation.
Patients must have adequate bone marrow function as evidenced by all of the following: ANC ≥ 1,500/microliter (mcL); platelets ≥ 100,000/mcL; Hemoglobin ≥ 9 g/dL. These results must be obtained within 28 days prior to randomization.
Cancer
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY OF SIRNA GENE SILENCING FOR THE TREATMENT OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) IN PARTICIPANTS WITH GENETIC RISK FACTORS

This is a Phase 2 drug study, using a precision medicine approach to treat a chronic liver disease called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in individuals at increased genetic risk for this condition. The primary objective of the study is to evaluate the effect of the study drug, ALN-HSD, on the histopathologic (liver biopsy) assessment of liver fibrosis. The study has a screening period of up to 12 weeks (day -84 to -1) (which includes a genetic pre-screening assessment, double-blind placebo-controlled treatment period of 52 weeks (day 1 to 365), and an off-drug safety follow-up period of 32 weeks (day 366 to 589). In total, the study duration is approximately 100 weeks. The study drug, or placebo, would be administered subcutaneously (through a fine needle in the belly) every 4 weeks, for a total of 13 doses. During the course of the study, there will be approximately 20 visits, which will take place in the clinical research center of our hospital. At these visits, participants will receive the injections, and be evaluated for vital signs, have regular bloodwork, receive a physical, and answer questions about their well being.

There will be up to 20 in person visits. The screening visits will include bloodwork, vitals, body measurements, and some additional scans. After randomization, each visit will occur approximately every two weeks and will include blood work and a physical at each visit, in addition to the administration of the study drug.

$2548

Yes
 

Karen Krok
Wes Heinle - at jheinle@pennstatehealth.psu.edu
Medicine: Gastroenterology and Hepatology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT05519475
STUDY00025117
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Adult male or female ≥18 years and ≤75 years of age.
A diagnosis of NASH with fibrosis (F) stage 2 or 3

Exclusion Criteria:
Cirrhosis from any cause, including cirrhosis due to NASH
Alcoholic liver disease
History of Type 1 diabetes
Digestive Systems & Liver Disease
Experimental drug compared to a placebo/”sugar pill”
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Ecological Decision-Making of COVID-19 Vaccination

This is an online survey study that examines factors impacting people’s COVID-19 vaccination decision-making. In the survey, participants will answer various questions about COVID-19 and COVID-19 vaccines, such as their personal experience, their perception and knowledge of COVID-19 vaccines.

No
 

Aiping Xiong
axx29@psu.edu
Information Sciences and Technology (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00017483
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
18 years or order
An active undergraduate student or graduate student enrolled in classes at University Park campus
currently is residing in the United States

Exclusion Criteria:
Younger than 18 years old
not a currently enrolled undergraduate student or graduate student, of PSU, University Park
currently is not residing in the United States
COVID-19
I'm interested
Share via email

A comparison of VR and MR in Human-ECA interaction

We are conducting this study to investigate whether different platforms of immersive technology influence the experiences of users when interacting with an embodied conversational agent. We are particularly interested in studying the effects of platform on users’ feelings of presence and social presence when comparing virtual and mixed reality environments.

Yes
 

Pejman Sajjadi
Pejman Sajjadi - at sfs5919@psu.edu
Geography (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00013361
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Corrected to near corrected vision
English speaking

Exclusion Criteria:
Hearing impairment
Education
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,

The Ketogenic Diet, Blood Lipids, and Heart Health in Healthy Adults with Differing BMI

The purpose of this feeding study is to examine if there is a difference in the effect of feeding a very low carbohydrate diet to people with normal weight and people with obesity. Participants will be asked to eat a very low carbohydrate diet, also known as a ketogenic diet, for 28 days. This diet will be provided to participants and includes 3 meals, some snacks, and beverages daily. Measurements of blood markers (fats, sugar, insulin, cholesterol), blood pressure, heart health, and body composition will be done at the start and end of the study.

In this study, you will be asked to consume a ketogenic diet for 28 days. This diet will be provided to you and includes 3 meals, some snacks, and beverages daily. This diet will meet your energy and nutrient needs. You will be asked to not eat any foods outside of what is provided by the study and consume no alcohol. Testing will be conducted on two consecutive days at the start of the study and the end of the study (a total of 4 testing days). For these visits, you will need to fast for 12 hours prior and avoid alcohol for 48 hours prior. At these visits, we will take a blood draw, measure your body weight, body composition, and preform non-invasive tests to assess your heart health.

$150

Yes
 

Kristina Petersen
Zachary DiMattia - at dchlab@psu.edu or 866-778-3438
Nutritional Sciences (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
NCT06515912
STUDY00024970
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Age: 25 to 45 years
BMI: 18.5-22 or 30-35 kg/m^2
LDL cholesterol: <100 mg/dL
Blood glucose: <126 mg/dL
Triglycerides: <350 mg/dL

Exclusion Criteria:
Diagnosis of heart disease, stroke, kidney or liver disease
Current use of tobacco-containing products or (≤6 months) cessation
Pregnant or nursing individuals
Allergy or unwilling to eat study foods
Previously consumed a ketogenic diet for > 1 week
Food & Nutrition, Heart & Vascular, Prevention
Not applicable
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,

Social Values for Bird Conservation in PA

The purpose of this study is to examine public attitudes and willingness to pay for bird conversation activities on private forest lands.

No
 

Melissa Kreye
Melissa Kreye - at mxk1244@psu.edu
Ecosystem Science and Management (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00013358
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
lives in Pennsylvania

Exclusion Criteria:
Does not live in Pennsylvania
Education
I'm interested
Share via email

Pictorial Influence on Sentence Comprehension

This behavioral study will examine the influence of pictorial primes on general knowledge questions. A participant will be shown a cartoon-type picture prior to the presentation of a question. They will be asked to answer the question verbally. This study aims to determine the influence of pictorial primes on memory recall and retrieval.

Yes
 

Marissa Scotto
Marissa Scotto - at mxs2620@psu.edu or 814-867-3033
Psychology (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
STUDY00010406
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Must be over the age of 18
Must be a native English speaker

Exclusion Criteria:
Under the age of 18
Not a native English speaker
Education, Language & Linguistics
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,

Evaluation of the Immune Response and Antigenic Signature of Patients with Babesia Infection in Pennsylvania with the Aim of Developing a Rapid Diagnostic Test

We are evaluating patients who have been infected with Babesia. Babesia is a blood parasite that is acquired from ticks. The number of cases seen in Pennsylvania every year has been increasing. We intend to evaluate the blood of patients acutely infected with Babesiosis and review for possible simultaneous co-infections. We will compare those infected patients with the blood of healthy individuals. The goal is to identify proteins in the blood of acutely infected patients that are specific for Babesia and also evaluate the prevalence of patient's who have contracted a co-infection from the tick vector that transmitted the Babesia infection. The identification of the specific bacterial/parasitic antigens could then be used to create rapid diagnostic tests and help clinicians increase awareness of these tick-borne diseases.

We will obtain basic demographic information and past medical history. We will obtain two 10ml samples of blood. The blood will then be stored and ultimately sent to Antigen Discovery, Inc for proteomic array screening.

Yes
 

David Ingram
David Ingram - at dingram@pennstatehealth.psu.edu or 717-531-8881
Medicine: Infectious Diseases and Epidemiology (HERSHEY)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00011530
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Healthy
18 years or older

Exclusion Criteria:
Active Cancer
History of having your spleen removed
History of liver or kidney disease
HIV
Diabetes
Infectious Diseases & Immune System
I'm interested
Share via email
Show 3 locations

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,
Reading, PA ,
Wilkes-Barre/Scranton Area, PA ,

A151216-Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (Alchemist)

Purpose of study is to examine lung cancer patients' surgically removed tumors for certain genetic changes and to possibly refer these patients to a treatment study with drugs that may specifically these tumors.

Patients will be registered to the trial after surgical intervention. One vial of peripheral blood and a tissue block (or scrolls) will be submitted to the study. Once testing is completed, subject is notified if they are eligible for one of the sub protocols.

Yes
 

Marc Rovito
Michelle Eschbach - at meschbach@pennstatehealth.psu.edu or 610-378-2336
Cancer Institute (ST. JOSEPH)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT02194738
AFFIL0A151216
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Surgically resected non-small cell lung cancer
Pathologic stage IIIA, II (IIA or IIB) or large IB (defined as size ≥4 cm).
Tissue available for the required analyses

Exclusion Criteria:
No patients with recurrence of lung cancer after prior resection
No prior treatment with agents targeting EGFR mutation, ALK rearrangement, and PD1/PD-L1/CTLA-4.
Cancer
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Reading, PA ,

Rapid Motor Regulation Mechanism for Arm Movement in Response to Visual Motion

This study looks at the relationship between motor control via. arm movement and visual stimuli. After participating in brief calibration protocol for the eye tracking system, participants will be moving a robotic handle to interact with visual stimuli during various tasks. Participants will spend approximately 2 hours in the lab.

There will be one approximately 2-hour visit. They will then be asked to complete 20-25 blocks of hand movements while looking at a moving virtual stimulus with a large visual background. Participants will receive regular breaks during the experiment.

$20

Yes
 

Tarkeshwar Singh
Tarkeshwar Singh - at tsingh@psu.edu or 814-865-7851
Kinesiology (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00023522
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Between 18-65 years old
Right-hand dominant
Normal or corrected-to-normal vision
Able to sit upright in a chair for long periods
Able to grasp and move objects with both hands

Exclusion Criteria:
Any history of neurological disorders
Any history of musculoskeletal disorders
Eye or vision problems (e.g., cataracts, glaucoma, a detached retina or macular degeneration)
Cognitive impairment such that informed consent cannot be obtained, or that participant would not be safe with the protocol
Medication that could make the participant drowsy or tired during the experiment
Neurology, Vision & Eyes
Not applicable
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,

Understanding healthcare workers perception and knowledge of dysphagia

The purpose of this study is to gain a greater understanding of healthcare workers’ knowledge of and perception of dysphagia in older adults. Study participants will fill out a survey/questionnaire in a single study session. This is expected to take 15-20 minutes.

You will be asked to complete a single, brief survey. It will take no more than 15-20 minutes.

No
 

Aarthi Madhavan
Aarthi Madhavan - at aarthi@psu.edu
Communication Sciences and Disorders (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT00000000
STUDY00024236
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Age 18 and older
Active healthcare workers or care providers for community dwelling older adults over 60 years old
Working with older adults
English proficiency at 8th grade level

Exclusion Criteria:
Never worked with older adults
Not working clinically currently
Diagnosed mild cognitive impairment or dementia
Infectious Diseases & Immune System, Food & Nutrition, Prevention
Not applicable
I'm interested
Share via email
See this study on ClinicalTrials.gov

Evaluation of Patellar Tendon Biomechanics

The objective of the study is to evaluate the condition of the patellar tendon with Ultrasound imaging. Ultrasound imaging will be explored as an accessible and non-invasive imaging modality to quantify tendon parameters (length, thickness, width, and neovascularization). Participants will sign informed consent and participate in an imaging session that will last approximately two hours. If the Ultrasound measurements prove feasible, they will provide insight into the biomechanical and biological mechanisms that contribute to tendon injury. It is important to understand how these parameters change among patients and healthy individuals with varying degrees of activity levels.

There will be one ultrasound session that will last approximately 2 hours. Ultrasound imaging will be performed at 342 Leonhard Building.

$20 gift card

Yes
 

Daniel Cortes Correales
Amanda Sargen - at ajs9367@psu.edu or 717-673-4218
Mechanical and Nuclear Engineering (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00026075
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Age 18 - 35

Exclusion Criteria:
Prior knee surgery
Arthritis & Rheumatic Diseases, Sports Medicine, Pain Management
Not applicable
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,

Perception of English sentences in context

This study tracks the eye movements of 30 adults to gather information on how they process sentences when presented in a context.

Yes
 

Frances Blanchette
Frances Blanchette - at fkb1@psu.edu or 814-863-7392
Psychology (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00007476
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
adult (18+)
native speaker of American English
grew up mainly in the US

Exclusion Criteria:
under 18 years of age
not a native speaker of American English
did not grow up mainly in the US
Language & Linguistics
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,